Zenas BioPharma, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
ZBIO$28.57+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, · · December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| Assets | | | | | | |
| Current assets: | | | | | | |
| Cash and cash equivalents | | $110,641 | | $319,742 | ||
| Short-term investments | | | 232,551 | | | 31,024 |
| Restricted cash | | | — | | | 90 |
| Prepaid expenses and other current assets | | | 7,979 | | | 5,067 |
| Total current assets | | | 351,171 | | | 355,923 |
| Property and equipment, net | | | 34 | | | 185 |
| Operating lease right-of-use assets, net | | | 1,354 | | | 1,004 |
| Long-term investments | | | 17,272 | | | — |
| Other non-current assets | | | 13,809 | | | 12,856 |
| Total assets | | $383,640 | | $369,968 | ||
| Liabilities and Stockholders’ Equity | | | | | | |
| Current liabilities: | | | | | | |
| Accounts payable | | $7,111 | | $17,136 | ||
| Accrued expenses | | | 54,423 | | | 39,371 |
| Operating lease liabilities, current | | | 1,115 | | | 785 |
| Total current liabilities | | | 62,649 | | | 57,292 |
| Long-term liabilities: | | | | | | |
| Royalty obligation | | | 78,636 | | | — |
| Operating lease liabilities, less current portion | | | 211 | | | 218 |
| Total long-term liabilities | | | 78,847 | | | 218 |
| Total liabilities | | | 141,496 | | | 57,510 |
| Commitments and contingencies (Note 13) | | | | | | |
| Stockholders’ equity: | | | | | | |
| Preferred stock, par value $0.0001 per share; 25,000,000 shares authorized and no shares issued and outstanding as of December 31, 2025 and December 31, 2024 | | | — | | | — |
| Common stock, par value $0.0001 per share; 175,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 54,485,518 and 41,793,412 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | | | 5 | | | 4 |
| Additional paid-in capital | | | 1,007,331 | | | 699,651 |
| Accumulated other comprehensive (loss) income | | | (64) | | | 194 |
| Accumulated deficit | | | (765,128) | | | (387,391) |
| Total stockholders’ equity | | | 242,144 | | | 312,458 |
| Total liabilities and stockholders’ equity | | $383,640 | | $369,968 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.